Unlocking the next generation of
Our goal is to create a
BSF Enterprise is unlocking the next generation of biotech solutions through an acquisition-led growth strategy to drive the development of lab-grown tissues. Cell-based tissue engineering can be used to generate cultured meat, lab-grown leather, human corneas, collagen growth and skin substitutes. This technology will contribute to a radical transformation of the delivery of sustainable solutions across a variety of sectors.
Investing in the rapidly growing tissue engineering market.
We acquire, commercialise and develop tissue engineering technologies with the objective of licensing out our IP to manufacturers, wholesalers and distributors to achieve a stage where products can be manufactured at scale.
Our first acquisition, 3D Bio-Tissues, is a tissue engineering company spun out of the University of Newcastle upon Tyne which printed the world’s first human corneas.
Patented technology produces the highest quality animal tissue.
Proprietary ‘Tissue Templating’ technology produces tissue with natural structure and function.
Diverse products with near term revenue opportunities.
Lab-grown meat and leather; corneas; skincare; animal-free cell growth agent.
Operating in fast-growing markets.
410% CAGR (2021 to 2030) for lab-grown meat; 12.7m people awaiting cornea transplant.
Experienced Board with a clear strategy.
Acquire, develop and license technology in cultured animal tissue technologies and related products.
Strong management team with long-term history in tissue engineering.
Globally recognised experts in cell biology.